



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/695,766 10.		0/2003	Tatsuo Suzuki	2003_1580A	6922
513	7590	06/08/2005		EXAMINER	
WENDERC 2033 K STRI		& PONACK, L	LEITH, PA	LEITH, PATRICIA A	
SUITE 800	CEIN.W.		ART UNIT	PAPER NUMBER	
WASHINGT	ON, DC 20	0006-1021	1654		

DATE MAILED: 06/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		T 2 22 22 22 22 22 22 22 22 22 22 22 22				
•		Application No.	Applicant(s)			
	Office Action Summer:	10/695,766	SUZUKI ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Patricia Leith	1654			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a repl period for reply is specified above, the maximum statutory period irre to reply within the set or extended period for reply will, by statut reply received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be tirely within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed /s will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on					
		— s action is non-final.				
3)						
Disposit	ion of Claims					
4) Claim(s) 1-28 is/are pending in the application. 4a) Of the above claim(s) 5,6,13,14,19,20,27 and 28 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-4,7-11,15-18 and 21-26 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers					
10)⊠	The specification is objected to by the Examina The drawing(s) filed on 30 October 2003 is/are Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examination.	e: a) accepted or b) objected or b) objected or b) objected or abeyance. Se ction is required if the drawing(s) is ob	e 37 CFR 1.85(a). pjected to. See 37 CFR 1.121(d).			
Priority (under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachmen	t(s) te of References Cited (PTO-892)	4) 🔲 Interview Summary	y (PTO-413)			
2) Notice 3) Inform	te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 or No(s)/Mail Date	Paper No(s)/Mail D	ate Patent Application (PTO-152)			

Application/Control Number: 10/695,766

Art Unit: 1654

DETAILED ACTION

Page 2

Election/Restrictions

Claims 13, 14, 27 and 28 are hereby withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 11/16/04.

Applicant's election of Tricholoma and mycelium in the reply filed on 1/31/05 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Because claims 5, 6, 19 and 20 are directed toward a non-elected species, these claims are also withdrawn from further consideration on the merits.

Claims 1-4, 7-11, 15-18 and 21-26 were examined on their merits.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Art Unit: 1654

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-4, 7-11, 15-18 and 21-25 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

All of these claims are directed toward naturally-occurring fungi. In order to overcome this rejection, prior to any instance of 'Tricholoma' there should be a statement reading; 'a biologically pure culture of'. Correction is necessary.

Specification/Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to and claims 1-4, 7-11, 15-18 and 21-26 are rejected under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention, failing to provide an enabling disclosure and failing to present the best mode contemplated by applicant for carrying out the invention without complete evidence either that the claimed biological materials are known and

readily available to the public or complete evidence of the deposit of the biological material.

It is apparent that the microorganism(s) is/are required to practice the claimed invention. As a required element it/they must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. If it/they is/are not so obtainable or available, the enablement requirements of 35 U.S.C. § 112, first paragraph, may be satisfied by a deposit of the microorganism(s). See 37 C.F.R. § 1.802.

The specification does not provide a repeatable process for obtaining the microorganism(s) and it is not apparent if the claimed strain of Tricholoma is readily available to the public. The specification must contain the date that the microorganism(s) was/were deposited, the name of the microorganism(s) and the address of where the culture was deposited.

If the deposit has been made under the terms of the Budapest Treaty, then an affidavit or declaration by Applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney or record over his/her signature, and registration number, stating that the specific strain(s) has/have been deposited under the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably

Art Unit: 1654

removed upon the granting of a patent, would satisfy the deposit requirements. See 37 C.F.R. § 1.808.

If the deposit(s) has/have <u>not</u> been made under the Budapest Treaty, then in order to certify that the deposit(s) meets the criteria set forth in 37 C.F.R. § 1.801-1.809, Applicant(s) may provide assurance of compliance by an affidavit or declaration, or by a statement by an Attorney of record over his/her signature and registration number, showing that:

- (a) during the pendency of this application, access to the invention will be afforded to the Commissioner upon request;
- (b) <u>all</u> restrictions upon availability to the public will be irrevocably removed upon granting of the patent;
- (c) the deposit(s) will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer;
- (d) a viability statement in accordance with the provisions of 37 C.F.R. § 1.807; and
- (e) the deposit will be replaced should it become necessary due to inviability, contamination or loss of capability to function in the manner described in the specification.

Art Unit: 1654

In addition, the identifying information set forth in 37 C.F.R. § 1.809 (d) should be added to the specification. See 37 C.F.R. § 1.803-1.809 for additional explanation of these requirements.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention, failing to provide an enabling disclosure and failing to present the best mode contemplated by applicant for carrying out the invention without complete evidence either that the claimed biological materials are known and readily available to the public or complete evidence of the deposit of the biological material.

If the deposit <u>has</u> been made under the terms of the Budapest Treaty, then an affidavit or declaration by Applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney or record over his/her signature, and registration number, stating that the specific strain has been deposited under the Budapest Treaty <u>and</u> that <u>all</u> restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. See 37 C.F.R. § 1.808.

As it appears in bold, *supra*, it is noted that the address for National Institute of Bioscience and Human-Technology (NIBH) Agency of Industrial Science and

Application/Control Number: 10/695,766

Art Unit: 1654

Technology Ministry of International Trade and Industry is 1-3, Higashi 1- chome,

Tsukuba-shi, Ibaraki-ken 305, Japan which should be indicated in the Instant

specification. It is further noted, as indicated above, that the Specification should clearly

Page 7

state that the culture is readily available, or will be readily available to the public.

Claim 26 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply

with the written description requirement. The claim(s) contains subject matter which

was not described in the specification in such a way as to reasonably convey to one

skilled in the relevant art that the inventor(s), at the time the application was filed, had

possession of the claimed invention.

Claim 26 states 'and an antibiotic'. It is deemed that the Instant specification

does not provide support for every known antibiotic, in that it does not set forth a

reasonable number of examples from the genus of all known antibiotics. Due to this

lack of support in the Instant specification, it is deemed that Applicants were not in

possession of a culture of Tricholoma matsutake and every known antibiotic.

Correction is necessary.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 7-11, 15-17, 21-25 are rejected under 35 U.S.C. 102(b) as being anticipated by Shimazono, H. (JP 53162929 – English Abstract).

Shimazono, H. (JP 355118389A – English Abstract) disclosed that Tricholoma matsutake (Matsutake) and an extract thereof were well known in the art (see English Abstract). It is pointed out that these claims are simply drawn to the mycelium of the mushroom, which is the filamentous vegetative portion of a fungus, which is an inherent property of the Matsutake. Further, language which states 'is intended for' is merely intended use language which does not materially change the composition; i.e., claims 7-11. Additionally, wherein claims 15-17 which state the composition is 'a preventive or therapeutic food for infection with a pathogenic microorganism, containing a member of basidiomycetes...' is also intended use language which does not change the structure and/or function of the composition. Applicant is asked to review In re Hack, 245 F.2d 246, 248, 114 USPQ 161, 163 (CCPA 1957). AWhen the claim recites using an old composition or structure and the Ause≅ is directed to a result or property of that composition or structure, then the claim is anticipated≅ (MPEP 2100 pp. 2113).

Application/Control Number: 10/695,766

Art Unit: 1654

No Claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia Leith whose telephone number is (571) 272-0968. The examiner can normally be reached from 8:30am-5:00pm Monday – Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patricia Leith Primary Examiner Art Unit 1654

Vatrice Lail

Page 9

06/06/05